Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Free Cash Flow (2022 - 2025)

Corvus Pharmaceuticals has reported Free Cash Flow over the past 4 years, most recently at -$9.2 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$9.2 million for Q4 2025, down 8.87% from a year ago — trailing twelve months through Dec 2025 was -$33.0 million (down 29.68% YoY), and the annual figure for FY2025 was -$33.0 million, down 29.68%.
  • Free Cash Flow for Q4 2025 was -$9.2 million at Corvus Pharmaceuticals, up from -$9.6 million in the prior quarter.
  • Over the last five years, Free Cash Flow for CRVS hit a ceiling of -$5.2 million in Q1 2024 and a floor of -$9.6 million in Q3 2025.
  • Median Free Cash Flow over the past 4 years was -$6.4 million (2022), compared with a mean of -$6.9 million.
  • Peak annual rise in Free Cash Flow hit 36.69% in 2024, while the deepest fall reached 63.83% in 2024.
  • Corvus Pharmaceuticals' Free Cash Flow stood at -$7.5 million in 2022, then soared by 31.54% to -$5.2 million in 2023, then tumbled by 63.83% to -$8.5 million in 2024, then dropped by 8.87% to -$9.2 million in 2025.
  • The last three reported values for Free Cash Flow were -$9.2 million (Q4 2025), -$9.6 million (Q3 2025), and -$5.9 million (Q2 2025) per Business Quant data.